Veeva Systems Inc. (VEEV): Balancing Analyst Skepticism with Innovation and Strategic Partnerships

Veeva Systems (NYSE:VEEV) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Veeva Systems (NYSE:VEEV) unveiled Veeva eSource, a new Veeva SiteVault tailored to eliminate manual clinical trial processes and increase data quality. On January 13, Goldman Sachs cut its rating on Veeva Systems to Sell and set a price target of $215, citing concerns that the company may struggle to maintain its historic growth pace as some of its core products mature.

Analyst Adam Hotchkiss flagged rising competition in Veeva’s Commercial segment, particularly from Salesforce’s Life Sciences Cloud, and noted that visibility around growth from newer offerings remains limited. Although Veeva’s R&D solutions continue to show promise, Goldman Sachs believes the company will face hurdles in sustaining the high‑teens growth needed to hit its 2030 goals, leaving it less compelling compared with peers that offer stronger upside.

On January 8, Veeva Systems and BioMarin Pharmaceutical (NASDAQ:BMRN) announced they are expanding their long-term enterprise agreement, strengthening a partnership that has already been in place for several years. The renewed deal is designed to boost BioMarin’s efficiency and agility, while improving the overall experience for healthcare providers and patients through Veeva’s suite of software, data, services, and consulting capabilities.

BioMarin’s CEO, Alexander Hardy, described the agreement as an important milestone in the company’s digital transformation, noting that combining BioMarin’s scientific expertise with Veeva’s technology will help deliver breakthrough medicines to patients more quickly. Veeva CEO Peter Gassner highlighted the companies’ shared commitment to product excellence and customer success, adding that the expanded collaboration will further support BioMarin’s global mission to advance innovative therapies.

Veeva Systems Inc. (NYSE:VEEV) is a leading global provider of industry-specific, cloud-based software, data, and analytics for the life sciences (pharmaceutical, biotech, and medical device) industry.

While we acknowledge the potential of VEEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Best Cheap Stocks to Buy for 2026 and 10 Stocks with Huge Growth Potential According to the Media.

Disclosure: None. This article is originally published at Insider Monkey.